Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Pegfilgrastim Given Same Day As or Day After Carboplatin and Docetaxel in Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC)
Completed
- Conditions
- Lung CancerNon-Small Cell Lung Cancer
- Interventions
- Other: PI Discretion
- First Posted Date
- 2004-10-27
- Last Posted Date
- 2009-02-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 90
- Registration Number
- NCT00094822
Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer
Phase 2
Completed
- Conditions
- Colon CancerColorectal CancerRectal Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2004-10-26
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 252
- Registration Number
- NCT00094809
Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis
Phase 3
Completed
- Conditions
- Kidney DiseaseChronic Kidney Disease
- First Posted Date
- 2004-10-20
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 400
- Registration Number
- NCT00094484
Preference of Rheumatoid Arthritis (RA) Patients of Enbrel® (Etanercept) Auto-Injector Versus Enbrel® Pre-Filled Syringes
Phase 4
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2004-10-18
- Last Posted Date
- 2008-12-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 215
- Registration Number
- NCT00094341
Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease
Phase 3
Completed
- Conditions
- Kidney DiseaseChronic Kidney Disease
- Interventions
- First Posted Date
- 2004-10-11
- Last Posted Date
- 2013-05-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1100
- Registration Number
- NCT00093977
Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2013-05-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 71
- Registration Number
- NCT00093873
Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)
Phase 3
Completed
- Conditions
- Kidney DiseaseDiabetes MellitusAnemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2004-09-29
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 4038
- Registration Number
- NCT00093015
Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Breast CancerBone Metastases in Subjects With Advanced Breast CancerMetastases
- Interventions
- Biological: DenosumabDrug: IV Bisphosphonates
- First Posted Date
- 2004-09-21
- Last Posted Date
- 2014-01-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 255
- Registration Number
- NCT00091832
Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis
- First Posted Date
- 2004-09-21
- Last Posted Date
- 2010-12-31
- Lead Sponsor
- Amgen
- Target Recruit Count
- 332
- Registration Number
- NCT00091793
Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer
- First Posted Date
- 2004-09-21
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1000
- Registration Number
- NCT00091858
© Copyright 2025. All Rights Reserved by MedPath